Becton Dickinson and (NYSE:BDX) and AdvanSource Biomaterials Corpration (OTCMKTS:ASNB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.
Risk and Volatility
Becton Dickinson and has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, AdvanSource Biomaterials Corpration has a beta of -2.96, indicating that its share price is 396% less volatile than the S&P 500.
This table compares Becton Dickinson and and AdvanSource Biomaterials Corpration’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton Dickinson and||5.88%||14.58%||5.81%|
|AdvanSource Biomaterials Corpration||10.09%||-62.83%||11.21%|
Becton Dickinson and pays an annual dividend of $3.08 per share and has a dividend yield of 1.3%. AdvanSource Biomaterials Corpration does not pay a dividend. Becton Dickinson and pays out 28.0% of its earnings in the form of a dividend. Becton Dickinson and has raised its dividend for 47 consecutive years.
Valuation and Earnings
This table compares Becton Dickinson and and AdvanSource Biomaterials Corpration’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Becton Dickinson and||$15.98 billion||3.85||$311.00 million||$11.01||20.74|
|AdvanSource Biomaterials Corpration||$2.92 million||0.63||-$200,000.00||N/A||N/A|
Becton Dickinson and has higher revenue and earnings than AdvanSource Biomaterials Corpration.
Institutional and Insider Ownership
85.2% of Becton Dickinson and shares are owned by institutional investors. 0.1% of Becton Dickinson and shares are owned by insiders. Comparatively, 7.8% of AdvanSource Biomaterials Corpration shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Becton Dickinson and and AdvanSource Biomaterials Corpration, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton Dickinson and||0||4||7||1||2.75|
|AdvanSource Biomaterials Corpration||0||0||0||0||N/A|
Becton Dickinson and presently has a consensus price target of $256.33, suggesting a potential upside of 12.25%. Given Becton Dickinson and’s higher probable upside, research analysts clearly believe Becton Dickinson and is more favorable than AdvanSource Biomaterials Corpration.
Becton Dickinson and beats AdvanSource Biomaterials Corpration on 12 of the 16 factors compared between the two stocks.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
AdvanSource Biomaterials Corpration Company Profile
AdvanSource Biomaterials Corp. engages in the development of polymer materials which provide critical characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. Its products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Wilmington, MA.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.